The molecular bacterial load (MBL) assay is a new tuberculosis biomarker which provides results in ∼4 hours. The relationship between MBL and time-to-positivity (TTP) has not been thoroughly studied and predictive models do not exist. We aimed to develop a model for MBL and identify the MBL-TTP relationship in patients. The model was developed on data from 105 tuberculosis patients from Malawi, Mozambique and Tanzania with joint MBL and TTP observations quantified from patient sputum collected for 12 weeks. MBL was quantified using polymerase chain reaction (PCR) of mycobacterial RNA and TTP using the Mycobacterial Growth Indicator Tube (MGIT) 960 system. Treatment consisted of isoniazid, pyrazinamide and ethambutol in standard doses togeth...
This work was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP)...
A molecular assay to quantify Mycobacterium tuberculosis is described. In vitro, 98% (n = 96) of spu...
Tuberculosis is a difficult disease to treat, a process made more harder as tools to monitor treatme...
The molecular bacterial load (MBL) assay is a new tuberculosis biomarker which provides results in ∼...
textabstractThe aim of the study is to compare counting of colony forming units (CFU), the time to p...
Biomarkers are quantifiable characteristics of biological processes. In Mycobacterium tuberculosis, ...
OBJECTIVES: The relationship between cfu and Mycobacterial Growth Indicator Tube (MGIT) time to posi...
Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achiev...
Molecular bacterial load assay (MBLA) rapidly quantifies viable Mycobacterium tuberculosis (Mtb) and...
The identification of sensitive, specific, and reliable biomarkers that can be quantified in the ear...
Bacterial killing in TB-patients with relapse was compared to patients achieving cure, measured by T...
We evaluated the use of the molecular bacterial load (MBL) assay, for measuring viable Mycobacterium...
We evaluated the use of the molecular bacterial load (MBL) assay, for measuring viable Mycobacterium...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
This work was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP)...
A molecular assay to quantify Mycobacterium tuberculosis is described. In vitro, 98% (n = 96) of spu...
Tuberculosis is a difficult disease to treat, a process made more harder as tools to monitor treatme...
The molecular bacterial load (MBL) assay is a new tuberculosis biomarker which provides results in ∼...
textabstractThe aim of the study is to compare counting of colony forming units (CFU), the time to p...
Biomarkers are quantifiable characteristics of biological processes. In Mycobacterium tuberculosis, ...
OBJECTIVES: The relationship between cfu and Mycobacterial Growth Indicator Tube (MGIT) time to posi...
Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achiev...
Molecular bacterial load assay (MBLA) rapidly quantifies viable Mycobacterium tuberculosis (Mtb) and...
The identification of sensitive, specific, and reliable biomarkers that can be quantified in the ear...
Bacterial killing in TB-patients with relapse was compared to patients achieving cure, measured by T...
We evaluated the use of the molecular bacterial load (MBL) assay, for measuring viable Mycobacterium...
We evaluated the use of the molecular bacterial load (MBL) assay, for measuring viable Mycobacterium...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
This work was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP)...
A molecular assay to quantify Mycobacterium tuberculosis is described. In vitro, 98% (n = 96) of spu...
Tuberculosis is a difficult disease to treat, a process made more harder as tools to monitor treatme...